Skip to main content

Articles

Page 7 of 13

  1. Acute myeloid leukemia (AML) with the t(8;21)(q22;q22) chromosomal translocation is among the most common subtypes of AML and produces the AML1-ETO (RUNX1-ETO, RUNX1-RUNX1T1) oncogenic fusion gene. AML1-ETO funct...

    Authors: Daniel T. Johnson, Amanda G. Davis, Jie-Hua Zhou, Edward D. Ball and Dong-Er Zhang
    Citation: Experimental Hematology & Oncology 2021 10:8
  2. Coronavirus disease 2019 (COVID-19) is associated with coagulation abnormalities which are indicators of higher mortality especially in severe cases.

    Authors: Runhui Zheng, Jing Zhou, Bin Song, Xia Zheng, Ming Zhong, Li Jiang, Chun Pan, Wei Zhang, Jiaan Xia, Nanshan Chen, Wenjuan Wu, Dingyu Zhang, Yin Xi, Zhimin Lin, Ying Pan, Xiaoqing Liu…
    Citation: Experimental Hematology & Oncology 2021 10:6
  3. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Two consecutively negative SARS-CoV-2 viral RNA test ( interv...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Yuanyuan Hao, Shuaike Zheng, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2021 10:5
  4. Classical Hodgkin lymphoma (cHL) and anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma (ALK+ ALCL) are B and T cell lymphomas respectively, which express the tumour necrosis factor receptor s...

    Authors: Zuoqiao Wu, Mary Nicoll and Robert J. Ingham
    Citation: Experimental Hematology & Oncology 2021 10:4
  5. Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are requi...

    Authors: Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas and Magne Børset
    Citation: Experimental Hematology & Oncology 2021 10:3
  6. The development of programmed cell death-1 inhibitor (PD-1) has shed light on the treatment of tumors with deficiencies in DNA mismatch repair system or microsatellite instability (dMMR/MSI). However, predicti...

    Authors: Qiao-Xuan Wang, Chun-Hua Qu, Yuan-Hong Gao, Pei-Rong Ding, Jing-Ping Yun, Dan Xie and Mu-Yan Cai
    Citation: Experimental Hematology & Oncology 2021 10:2
  7. Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1...

    Authors: Sakshi Jasra, Mohammed Kazemi, Nishi Shah, Jiahao Chen, Karen Fehn, Yanhua Wang, Ioannis Mantzaris, Noah Kornblum, Alejandro Sica, LizaMarie Bachier, Mendel Goldfinger, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Aditi Shastri and Amit Verma
    Citation: Experimental Hematology & Oncology 2021 10:1
  8. Authors: Ana Muntañola, Guillermo Villacampa, José Ángel Hernández-Rivas, Rosalía Alonso, Fátima Mirás, Santiago Osorio, Mónica Baile, Patricia Baltasar, Javier López Jiménez, Ines Hernandez-Rodriguez, Susana Valenciano, Ana Alfayate, Eva Gimeno, Abelardo Bárez, Ana C. Oliveira, Rosalía Riaza…
    Citation: Experimental Hematology & Oncology 2020 9:37
  9. CD44, a complex transmembrane glycoprotein, exists in multiple molecular forms, including the standard isoform CD44s and CD44 variant isoforms. CD44 participates in multiple physiological processes, and aberra...

    Authors: Hanxiao Xu, Mengke Niu, Xun Yuan, Kongming Wu and Aiguo Liu
    Citation: Experimental Hematology & Oncology 2020 9:36
  10. Studies of the gut microbiota (GM) have demonstrated the close link between human wellness and intestinal commensal bacteria, which mediate development of the host immune system. The dysbiosis, a disruption of...

    Authors: Jifeng Yu, Hao Sun, Weijie Cao, Lijie Han, Yongping Song, Dingming Wan and Zhongxing Jiang
    Citation: Experimental Hematology & Oncology 2020 9:35
  11. CD19-targeted CAR T cells therapy has shown remarkable efficacy in treatment of B cell malignancies. However, relapse of primary disease remains a major obstacle after CAR T cells therapy, and the majority of ...

    Authors: Hao Zhang, Pu Zhao and He Huang
    Citation: Experimental Hematology & Oncology 2020 9:34
  12. Cyclic adenosine monophosphate (cAMP) is the first discovered second messenger, which plays pivotal roles in cell signaling, and regulates many physiological and pathological processes. cAMP can regulate the t...

    Authors: Hongying Zhang, Qingbin Kong, Jiao Wang, Yangfu Jiang and Hui Hua
    Citation: Experimental Hematology & Oncology 2020 9:32
  13. T-cell acute lymphoblastic leukemia (T-ALL) is one of the hematological malignancies. With the applications of chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the cure rate of T-A...

    Authors: Ruyue Zheng, Menglin Li, Shujuan Wang and Yanfang Liu
    Citation: Experimental Hematology & Oncology 2020 9:31
  14. Outcomes of chronic myeloid leukemia (CML) has been improved dramatically in the past two decades, but survival levels of CML patients varied in regions. Comprehensive epidemiological research is necessary to ...

    Authors: Liqing Ning, Chuanyu Hu, Pingfan Lu, Yimei Que, Xiaojian Zhu and Dengju Li
    Citation: Experimental Hematology & Oncology 2020 9:29
  15. Pancreatic cancer is one of the most common causes of cancer-related deaths worldwide. The two major histological subtypes of pancreatic cancer are pancreatic ductal adenocarcinoma (PDAC), accounting for 90% o...

    Authors: He-Li Gao, Wen-Quan Wang, Xian-Jun Yu and Liang Liu
    Citation: Experimental Hematology & Oncology 2020 9:28
  16. Kidney cancer’s incidence and mortality vary in different regions and countries. To compare and interpret kidney cancer’s burden and change trends in the globe and in different countries, we conducted this stu...

    Authors: Xianguang Bai, Ming Yi, Bing Dong, Xinhua Zheng and Kongming Wu
    Citation: Experimental Hematology & Oncology 2020 9:27
  17. Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by constitutive activity of the tyrosine kinase BCR-ABL1. Although the introduction of tyrosine kinase inhibitors (TKIs) has substa...

    Authors: Theresa Klümper, Henrike Bruckmueller, Tobias Diewock, Meike Kaehler, Sierk Haenisch, Christiane Pott, Oliver Bruhn and Ingolf Cascorbi
    Citation: Experimental Hematology & Oncology 2020 9:26
  18. Novel corona virus caused pneumonia first reported in December, 2019 in Wuhan, China was later named COVID-19. Due to its special pathogenicity, COVID-19 transmitted with high speed beyond borders and has sign...

    Authors: Ehtisham Ul Haq, Jifeng Yu and Jiancheng Guo
    Citation: Experimental Hematology & Oncology 2020 9:24
  19. Pancreatic cancer continues to be one of the most aggressive malignant tumors. Work in recent years in cancer molecular biology has revealed that metabolic reprogramming is an additional hallmark of cancer tha...

    Authors: Mengqi Liu, Wensheng Liu, Yi Qin, Xiaowu Xu, Xianjun Yu, Qifeng Zhuo and Shunrong Ji
    Citation: Experimental Hematology & Oncology 2020 9:23
  20. Successful prevention of post-transplantation relapse after donor lymphocyte infusion (DLI) depends on its capability to mediate an effective graft-versus-leukemia (GVL) response while minimizing DLI-related t...

    Authors: Yong-Rim Kwon, Hye Joung Kim, Min-Jung Sohn, Ji-Young Lim, Kyung-Shin Park, Seok Lee, Nack-Gyun Chung, Dae-Chul Jeong, Chang-Ki Min and Yoo-Jin Kim
    Citation: Experimental Hematology & Oncology 2020 9:22
  21. Prognostic factors of poor outcome in patients with hematological malignancies and COVID-19 are poorly defined.

    Authors: José Luis Piñana, Rodrigo Martino, Irene García-García, Rocío Parody, María Dolores Morales, Gonzalo Benzo, Irene Gómez-Catalan, Rosa Coll, Ignacio De La Fuente, Alejandro Luna, Beatriz Merchán, Anabelle Chinea, Dunia de Miguel, Ana Serrano, Carmen Pérez, Carola Diaz…
    Citation: Experimental Hematology & Oncology 2020 9:21
  22. Despite the proven benefits of iron chelation therapy (ICT) in the management of chronic iron overload and related complications, compliance to long-term ICT is challenging. Results from the ECLIPSE study, an ...

    Authors: Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, Sibel Gunes, Susanne Crowe, Niamh Fagan, Beatrice Vincenzi and Giovan Battista Ruffo
    Citation: Experimental Hematology & Oncology 2020 9:20
  23. To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses.

    Authors: Il Seok Daniel Jeong, Huan Mo, Anthony Nguyen, Esther G. Chong, Hsin Hsiang Clarence Tsai, Justin Moyers, Matthew Kim, Curtis Lacy, Vivek Shah, Eric Lau, Yi Xu and Huynh Cao
    Citation: Experimental Hematology & Oncology 2020 9:19
  24. Pancreatic ductal adenocarcinoma (PDAC) has an extremely poor response to chemo- and (modest-dose conventionally fractionated) radio-therapy. Emerging evidence suggests that pancreatic stellate cells (PSCs) se...

    Authors: Pei Pei Che, Alessandro Gregori, Omidreza Firuzi, Max Dahele, Peter Sminia, Godefridus J. Peters and Elisa Giovannetti
    Citation: Experimental Hematology & Oncology 2020 9:18
  25. PD-L1 expression and tumour mutational burden (TMB) are both associated with the responses of multiple tumours to immune checkpoint inhibitor (ICI) therapy. However, their prevalence and correlations may diffe...

    Authors: Yanhui Chen, Yating Wang, Hongli Luo, Xue Meng, Wei Zhu, Di Wang, Hui Zeng and Henghui Zhang
    Citation: Experimental Hematology & Oncology 2020 9:17
  26. Coronavirus disease 2019 (COVID-19) is a novel infectious viral disease, which lacks well-established diagnostic laboratory parameters that could be used to evaluate disease severity, thromboembolism or cardio...

    Authors: Changqian Bao, Xiandong Tao, Wei Cui, Bin Yi, Tiewen Pan, Ken H. Young and Wenbin Qian
    Citation: Experimental Hematology & Oncology 2020 9:16
  27. Chimeric antigen receptor (CAR) T cell therapy is a new frontier in cancer therapy. The toxicity of cytokine release syndrome (CRS) has become one of the major challenges that limits the wider use of CAR T cel...

    Authors: Zhaonian Hao, Ruyuan Li, Li Meng, Zhiqiang Han and Zhenya Hong
    Citation: Experimental Hematology & Oncology 2020 9:15
  28. Breast cancer is the most diagnosed malignancy in females in the United States. The members of retinal determination gene network (RDGN) including DACH, EYA, as well as SIX families participate in the prolifer...

    Authors: Bing Dong, Ming Yi, Suxia Luo, Anping Li and Kongming Wu
    Citation: Experimental Hematology & Oncology 2020 9:13
  29. Human prostate cancer spheres endowed with stem cell properties have been obtained from androgen-dependent cell line LNCaP after exposure to an epigenomic modulator phenethyl isothiocynate (PEITC). Sphere cell...

    Authors: Jingjing Wu, Shundong Cang, Christina Liu, Whitman Ochiai and Jen Wei Chiao
    Citation: Experimental Hematology & Oncology 2020 9:12
  30. T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR T cell ...

    Authors: Liqing Kang, Xiaowen Tang, Jian Zhang, Minghao Li, Nan Xu, Wei Qi, Jingwen Tan, Xiaoyan Lou, Zhou Yu, Juanjuan Sun, Zhenkun Wang, Haiping Dai, Jia Chen, Guoqing Lin, Depei Wu and Lei Yu
    Citation: Experimental Hematology & Oncology 2020 9:11
  31. Immune cell infiltration in the tumor microenvironment (TME) affects tumor initiation, patients’ prognosis and immunotherapy strategies. However, their roles and interactions with genomics and molecular proces...

    Authors: Furong Liu, Lu Qin, Zhibin Liao, Jia Song, Chaoyi Yuan, Yachong Liu, Yu Wang, Heze Xu, Qiaofeng Zhang, Youliang Pei, Hongwei Zhang, Yonglong Pan, Xiaoping Chen, Zhanguo Zhang, Wanguang Zhang and Bixiang Zhang
    Citation: Experimental Hematology & Oncology 2020 9:10
  32. This letter describes the potential effect of B cell depletion on immune related adverse events associated with immune checkpoint inhibition. B cell depleting agents such as rituximab reduce B cell to plasma c...

    Authors: Rasmus Strøm Risbjerg, Mie Vennize Hansen, Anne Sofie Sørensen and Tue Wenzel Kragstrup
    Citation: Experimental Hematology & Oncology 2020 9:9
  33. Multiple myeloma is an incurable hematological malignancy characterized by a heterogeneous genetic and epigenetic landscape. Although a number of genetic aberrations associated with myeloma pathogenesis, progr...

    Authors: Xi Yun Zhang, Deepa Rajagopalan, Tae-Hoon Chung, Lissa Hooi, Tan Boon Toh, Johann Shane Tian, Masturah Bte Mohd Abdul Rashid, Noor Rashidha Bte Meera Sahib, Mengjie Gu, Jhin Jieh Lim, Wilson Wang, Wee Joo Chng, Sudhakar Jha and Edward Kai-Hua Chow
    Citation: Experimental Hematology & Oncology 2020 9:8
  34. Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor contro...

    Authors: Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, Kyaw Z. Thein, Aung Naing, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Filip Janku, Funda Meric-Bernstam, Razelle Kurzrock and Gerald Falchook
    Citation: Experimental Hematology & Oncology 2020 9:7
  35. The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX in autoimmune hemolytic anemia (AIHA) and microangiopathic he...

    Authors: Shih-Hsuan Chao, Yuh-Lih Chang, Jiin-Cherng Yen, Hsien-Tzung Liao, Tsai-Hung Wu, Chia-Li Yu, Chang-Youh Tsai and Yueh-Ching Chou
    Citation: Experimental Hematology & Oncology 2020 9:6
  36. The high-risk refractory and/or relapsed (R/R) childhood acute leukemia prognosis is poor, and allogeneic stem cell transplantation (allo-HSCT) is the most prudent treatment modality. However, there are limite...

    Authors: Binglei Zhang, Jian Zhou, Fengkuan Yu, Tianxin Lv, Baijun Fang, Dandan Fan, Zhenyu Ji and Yongping Song
    Citation: Experimental Hematology & Oncology 2020 9:5
  37. The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carr...

    Authors: Bingbing Wen, Weiwen You, Sitian Yang and Xin Du
    Citation: Experimental Hematology & Oncology 2020 9:3
  38. In this study, we retrospectively summarized the differences of molecular gene mutations between MDS and AML patients, as well as the young and older age groups of MDS and AML patients. We also analyzed the re...

    Authors: Jifeng Yu, Yingmei Li, Tao Li, Yafei Li, Haizhou Xing, Hui Sun, Ling Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie and Zhongxing Jiang
    Citation: Experimental Hematology & Oncology 2020 9:2
  39. Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs). Second mitochondria-derived activator of caspases (SM...

    Authors: Brianna M. Craver, Thanh Kim Nguyen, Jenny Nguyen, Hellen Nguyen, Christy Huynh, Sarah J. Morse and Angela G. Fleischman
    Citation: Experimental Hematology & Oncology 2020 9:1
  40. Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immun...

    Authors: Ming Yi, Bing Dong, Qian Chu and Kongming Wu
    Citation: Experimental Hematology & Oncology 2019 8:32

    The Article to this article has been published in Nature 2019 567:s41586-019-1032-7

  41. Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly bein...

    Authors: Muhammad Bilal Abid, Nirav N. Shah, Theresa C. Maatman and Parameswaran N. Hari
    Citation: Experimental Hematology & Oncology 2019 8:31
  42. Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...

    Authors: Shanshan Zhang, Zhaojian Gong, Peter O. Oladimeji, Duane G. Currier, Qipan Deng, Ming Liu, Taosheng Chen and Yong Li
    Citation: Experimental Hematology & Oncology 2019 8:30
  43. DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...

    Authors: Ming Yi, Bing Dong, Shuang Qin, Qian Chu, Kongming Wu and Suxia Luo
    Citation: Experimental Hematology & Oncology 2019 8:29
  44. Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine k...

    Authors: Juanjuan Zhao, Yongping Song and Delong Liu
    Citation: Experimental Hematology & Oncology 2019 8:28
  45. The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality c...

    Authors: Bill X. Wu, No-Joon Song, Brian P. Riesenberg and Zihai Li
    Citation: Experimental Hematology & Oncology 2019 8:27

Annual Journal Metrics

  • 2022 Citation Impact
    11.4 - 2-year Impact Factor
    7.3 - 5-year Impact Factor
    1.609 - SNIP (Source Normalized Impact per Paper)
    1.908 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage
    696,150 downloads
    375 Altmetric mentions